24-Hour Crisis Hotline: (877)SAFEGBC or (877)723-3422 Mental Health & Substance Abuse Issues

6502 Nursery Drive, Suite 100
Victoria, TX 77904
(361)575-0611
Fax: (361)578-5500
Regular Hours: M-Fri 8am - 5pm
Every 3rd Thurs of the Month - Extended Hours Until 7 pm

Medical Disorders
Resources
Basic InformationLookupsLatest News
Scientists Find Clues to Why AstraZeneca's Vaccine May Cause ClotsYou've Got Fungi in Your Lungs, and That's OKNon-Emergency Surgeries Are Rebounding, But Backlogs RemainPandemic Has Put Many Clinical Trials on HoldSupply of J&J COVID Vaccine to Drop 86 Percent Next WeekStressed, Exhausted: Frontline Workers Faced Big Mental Strain in PandemicNIH Starts Trial Looking at Rare Allergic Reactions to COVID VaccinesNot Just Keyboards: Many Types of Workers Can Develop Carpal TunnelBlack Women Are Dying of COVID at Much Higher Rates Than White MenTwo Vaccines Show Effectiveness Against Emerging COVID VariantsWomen More Prone to Concussion's Long-Term Harms: StudyCOVID Cases Climb in the Midwest as British Variant Takes Hold in U.S.'Heart-in-a-Box' Can Be Lifesaving, Matching Up Distant Donors With PatientsNo Proof COVID Vaccines Can Trigger Guillain-Barré SyndromeFor People With PAD, Exercise Can Be Tough But RewardingPublic Lost Trust in CDC During COVID Crisis: Poll1 in 3 COVID Survivors Struggle With Mental Health Issues Months LaterA Few People With COVID Went a Crowded Bar: Here's What HappenedNearly 8 in 10 School, Child Care Staff Have Gotten at Least 1 Dose of COVID Vaccine: CDCModerna COVID Vaccine Offers Protection for at Least 6 Months: StudyStrain of COVID Care Has Many Health Professionals Looking for an ExitCOVID Shot Earlier in Pregnancy Better for Baby: StudyDoctors' Group Says Antibiotics Can Be Taken for Shorter PeriodsIf You've Had COVID, One Vaccine Jab Will Do: StudyAbout 40,000 U.S. Children Have Lost a Parent to COVID-19Study Refutes Theory That Blood Type Affects COVID RiskHow Willing Are Americans to Donate COVID Vaccines to Other Countries?Got Your COVID Vaccine? Don't Stop Being Cautious, Experts SayCOVID Drove 23% Spike in U.S. Deaths In 2020Faster-Spreading COVID Variant Expanding in United StatesWhen Will America's Kids Get Their COVID Vaccines?AHA News: Why You Should Pay Attention to InflammationMany Recovering COVID Patients Show Signs of Long-Term Organ DamageCOVID Fears Mean More Cancers Are Being Diagnosed at Later StagesSome Hospitalized COVID Patients Develop SeizuresCan Vaccinations Stop COVID Transmission? College Study Aims to Find OutCDC Confirms COVID as Third Leading Cause of Death in 2020Research Reveals How Aspirin Helps Prevent Colon CancerPfizer Says Its COVID Vaccine Is Very Effective in Kids as Young as 12AHA News: The Secret to Good Health Is No Secret. So Why Is It So Hard to Achieve?'Couch Potato' Lifestyles Cause Up to 8% of Global Deaths: StudyHave to Travel During Spring Break? Here's How to Stay SafeNew Coronavirus Can Also Infect Cells in the MouthBiden, Top Health Officials Warn of Risk of Another COVID SurgeAHA News: Black Young Adults Face Higher Stroke Risk Than Their White PeersReal-World Proof That Pfizer, Moderna Vaccines Slash COVID InfectionsStudy Ties Gum Disease to High Blood PressureSmoking Rates High Among Surgery PatientsBiden Administration Working on 'Vaccine Passport' InitiativeSpring Activity Can Sometimes Bring Stress Fractures
Questions and AnswersLinks
Related Topics

Diabetes

Coronavirus Antibodies Appear to Stop Reinfection for Months

HealthDay News
by Ernie Mundell and Steven Reinberg
Updated: Feb 24th 2021

new article illustration

WEDNESDAY, Feb. 24, 2021 (HealthDay News) -- Protective immune system antibodies that develop after being infected with COVID-19 last for at least a few months, a new study suggests. And reinfection does seem to be relatively rare.

That could have big implications for public health and societies, including allowing people to return to physical workplaces and go to school, the researchers said.

"The data from this study suggest that people who have a positive result from a commercial antibody test appear to have substantial immunity to SARS-CoV-2, which means they may be at lower risk for future infection," researcher Dr. Lynne Penberthy, the associate director of the U.S. National Cancer Institute's Surveillance Research Program, said in an institute news release.

"Additional research is needed to understand how long this protection lasts, who may have limited protection, and how patient characteristics, such as comorbid conditions [other illnesses], may impact protection. We are nevertheless encouraged by this early finding," she said.

Antibody tests detect antibodies produced by the immune system in response to a specific foreign substance or infection, such as SARS-CoV-2.

For the study, researchers used a variety of sources to collect antibody test results for more than 3 million people. The data was sourced from two large health care data analytics companies, five commercial laboratories, electronic medical records and records from private insurers.

Nearly 12% of these blood tests came up positive for antibodies to COVID-19, the investigators found. Most of the remaining tests were negative.

Over time, the number of those with antibodies to COVID-19 dwindled to between 3% and 4%, and after three months less than 1% still had antibodies to COVID-19, the findings showed.

Still, the overall results are encouraging, said one expert in infectious disease.

"As more data accrues it has become clear that COVID-19 does follow the pattern of other infectious diseases in that recovery is associated with a level of protection from reinfection that persists for a significant period of time," said Dr. Amesh Adalja, a senior scholar at Johns Hopkins Center for Health Security, in Baltimore. "It will be critical to learn how long this immunity, which is conferred by antibodies and T-cells, persists."

The report was published online Feb. 17 in JAMA Internal Medicine.

More information

For more on COVID-19, head to the U.S. Centers for Disease Control and Prevention.

SOURCES: Amesh Adalja, MD, senior scholar, Johns Hopkins Center for Health Security, Baltimore; U.S. National Cancer Institute, news release, Feb. 24, 2021